Condition
Bacteremia Caused by Gram-Negative Bacteria
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Recruiting2
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06966284RecruitingPrimary
A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection
NCT06135350Phase 2Recruiting
Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV
NCT04238390Phase 3WithdrawnPrimary
Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection
Showing all 3 trials